Piper Sandler analyst David Amsellem maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback